ArticleFrontiers in immunology2025
The functional and clinical significance of nucleoporin NUP153 across human cancers: a systematic study based on multi-omics analysis and bench work validation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities.Cancer discovery · 2026Article
- Nuclear-Cytoplasmic Axis in Cancer: From Protein Mislocalization to Anticancer Drug Resistance.Oncology research · 2026Review
- Clinical Significance of SDC2 in Gastric Cancer: Insights From a Multi-Center Cohort Study.Cancer informatics · 2026Article
- Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy.Frontiers in immunology · 2025Article
- Glucokinase Regulatory Protein (GCKR) Links Metabolic Reprogramming With Immune Exclusion: Insights From a Pan-Cancer Analysis and Gastric Cancer Validation.Human mutation · 2025Article
- Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is a group of highly heterogeneous malignant diseases, and early diagnosis plays a crucial role in improving patient outcomes. Nucleoporins, including Nucleoporin (NUP)153, are involved in key cellular processes such as nucleocytoplasmic transport and cell cycle regulation. However, the role of NUP153 in cancer, especially its expression patterns, mutations, diagnostic value, and relationship with the tumour immune microenvironment, remains insufficiently explored. Methods: This study analysed NUP153 expression data from public databases such as TCGA and GTEx. Expression differences between tumour and normal tissues were assessed using Wilcoxon signed-rank tests. Gene set enrichment analysis (GSEA) was used to identify the biological functions and pathways related to NUP153. The relationship between NUP153 expression and immune cell infiltration was evaluated using the TIMER database, while drug sensitivity data were obtained from the GDSC and CTRP databases. Additionally, NUP153 expression in gastric cancer tissues was validated using immunohistochemistry and RT-qPCR. Results: NUP153 showed significant expression variation across cancers, with high levels in cholangiocarcinoma, colorectal cancer, and head and neck squamous cell carcinoma. In gastric cancer, NUP153 was markedly upregulated compared to adjacent non-cancerous tissues. High NUP153 expression was linked to tumour-associated macrophage infiltration and correlated with poor prognosis in some cancers like Kidney Renal Papillary Cell Carcinoma and Sarcoma. Drug genomics analysis revealed that NUP153 expression predicted chemotherapy resistance, with imatinib and 4.5-dianilinophthalimide showing potential for inhibition in multiple cancers. Single-cell analysis and spatial transcriptomics further revealed that NUP153 expression drives proliferative states in mucus-producing cells in gastric cancer, and its expression was associated with immune cell infiltration patterns, particularly neutrophil and macrophage distribution in the tumour microenvironment. Conclusion: Our findings indicate that NUP153 is a critical factor in multiple cancers, especially gastric cancer, where its elevated expression holds promise as a diagnostic and prognostic biomarker. The results indicate that NUP153 plays a key role in modulating the immune microenvironment and driving tumour progression, positioning it as a potential target for future therapeutic interventions. However, additional studies are required to elucidate the specific molecular mechanisms underlying NUP153's function in cancer and to explore its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.